Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse

Area of Science:

• Immunology
• Oncology
• Vaccine Development

Background:

• Dendritic cell (DC) vaccination's full potential against cancer remains unrealized.
• Understanding DC subset-specific anti-cancer immunity is crucial for preventing tumor recurrence.

Purpose of the Study:

• To compare the efficacy of conventional dendritic cell 1 (cDC1) and cDC2 vaccines in inducing anti-tumor immunity.
• To investigate the role of cDC1 vaccination in establishing long-term anti-tumor immune memory and preventing tumor relapse.

Main Methods:

• Generating dendritic cell vaccines using mouse splenic cDC1s or cDC2s pulsed with tumor cell lysates.
• Evaluating therapeutic and prophylactic anti-tumor responses in mouse models.
• Analyzing T cell populations, including tissue-resident memory T cells (Trm), in tumor relapse models.
• Correlating cDC1 and Trm abundance with patient survival in human breast cancer and melanoma datasets.

Main Results:

• cDC1-based vaccination elicited a robust effector and memory CD4+ and CD8+ T cell response, improving tumor control.
• Adjuvant or neoadjuvant cDC1 vaccination significantly enhanced anti-tumor immune memory, increasing CD4+ Trm and CD8+ memory T cell infiltrates.
• cDC1 vaccination led to complete prevention of tumor relapses in experimental models.
• Elevated cDC1 abundance positively correlated with CD4+ Trm presence and improved survival in human cancer patients.

Conclusions:

• cDC1-based vaccination is superior in inducing potent anti-tumor immune memory compared to cDC2 vaccination.
• cDC1 vaccination strategies hold significant promise for preventing cancer recurrence and improving patient survival.
• The correlation between cDC1s, Trm, and survival highlights their clinical relevance in breast cancer and melanoma.